| First‐in‐class pyrido[2,3‐d]pyrimidine‐2,4(1H,3H)‐diones against leishmaniasis and tuberculosis: Rationale, in vitro, ex vivo studies and mechanistic insights D Ramesh, D Sarkar, A Joji, M Singh, AK Mohanty, B G. Vijayakumar, ... Archiv der Pharmazie 355 (4), 2100440, 2022 | 8 | 2022 |
| Discovery of potent antimycobacterial agents targeting lumazine synthase (RibH) of Mycobacterium tuberculosis M Singh, A Dhanwal, A Verma, L Augustin, N Kumari, S Chakraborti, ... Scientific Reports 14 (1), 12170, 2024 | 2 | 2024 |
| The first-in-class pyrazole-based dual InhA-VEGFR inhibitors towards integrated antitubercular host-directed therapy MM Shaaban, M Teleb, HM Ragab, M Singh, BH Elwakil, LA Heikal, ... Bioorganic Chemistry 145, 107179, 2024 | 2 | 2024 |
| Elucidation of the essentiality of lumazine synthase (RibH) for Mycobacterium tuberculosis survival and discovery of potent inhibitors for enhanced … M Singh, A Dhanwal, A Verma, L Augustin, N Kumari, S Chakraborti, ... bioRxiv, 2023.07. 18.549608, 2023 | | 2023 |
